Akari Therapeutics (NASDAQ:AKTX) Share Price Crosses Below 50-Day Moving Average – Here’s Why

Akari Therapeutics, Plc (NASDAQ:AKTX) crossed below its fifty day moving average during trading on Friday . The stock has a fifty day moving average of $1.66 and traded as low as $0.97. Akari Therapeutics shares last traded at $0.97, with a volume of 95,614 shares.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on shares of Akari Therapeutics in a report on Saturday. They set a “sell” rating on the stock.

Akari Therapeutics Stock Down 1.2 %

The company has a fifty day moving average of $1.63 and a 200-day moving average of $2.73.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.